🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Jenburkt Pharmaceuticals Limited JENBURPH NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://jenburkt.com
Company Profile ↓
₹871.40
-15.09% 1Y
Mkt Cap₹384.57 Cr
P/E11.71
P/B2.12
Div. Yield2.18%
52W High₹1,051.20
52W Low₹871.40
Book Value₹446.47
EPS (TTM)₹74.42

Company Overview

Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations in India and internationally. The company offers therapeutic solutions, such as analgesic and antipyretics, anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants and antacids, aphrodisiac, atopic dermatitis, consumer division, cough and cold, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. It offers its products under the Allerzine, CartiSafe Forte, Crisbo, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, and Zydol Suspension brand names. The company also exports its products. It serves large government, semi-government institutions, missionary hospitals, and public sector enterprises. Jenburkt Pharmaceuticals Limited was incorporated in 1985 and is based in Mumbai, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 20.0%.

Consistent Profit Growth

Net profit has compounded at 12.2% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 11.7, below the sector median of 35.9.

Healthy Margins

Maintains a net profit margin of 19.5%.

Dividend Income

Offers a dividend yield of 2.18%.

Recent Developments

  • Mar 2026 Revenue of ₹168.74 Cr (+11.2% YoY); net profit ₹34.74 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +-0.0%, earnings -24.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 7.4%, profit CAGR 12.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:7.42%
1 Year:-0.00%

Compounded Profit Growth

5 Years:12.18%
1 Year:-24.50%

Stock Price Performance

1 Year:-15.09%
6 Months:-
3 Months:-
1 Month:-8.96%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 0% of range
₹871.40 ₹1,051.20
Trend Signals
  • RSI (14)30.77 · Neutral
Price Performance
1M-8.96%
1Y-15.09%
Valuation vs Sector

P/E of 11.71 is below the sector median of 35.90 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 20.0%.
  • Profit CAGR of 12.2% over 5 years.
  • Generates positive free cash flow.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
11.71
Industry PE
35.90
Forward P/E est.
15.51
PEG Ratio
-
Book Value
₹446.47
Price to Book
2.12
P/S
2.69
EV/EBITDA
8.91
Dividend Yield
2.18%

Growth (CAGR)

Revenue 5Y
7.42%
Profit 5Y
12.18%
Revenue (YoY)
-0.00%
Earnings (YoY)
-24.50%

Profitability & Returns

ROCE
20.03%
ROE
17.63%
ROA
15.37%
Profit Margin
19.46%
Op Margin
15.17%
Gross Margin
80.09%
EPS (Latest Qtr)
₹-
EPS (TTM)
₹74.42

Balance Sheet & Liquidity

Debt/Equity
1.26
Quick Ratio
3.52
Current Ratio
4.11
Debt
₹2.49 Cr
Total Assets
₹226.01 Cr
Current Assets
₹95.09 Cr
Working Capital
₹71.94 Cr

Ownership

Promoter Holding
61.18%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹384.57 Cr
Total Revenue (TTM)
₹168.73 Cr
EBITDA
₹41.94 Cr
Free Cash Flow
₹12.80 Cr
Operating Cash Flow
₹26.52 Cr
Shares Outstanding
₹44.13 L
Gross Margin
80.09%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 JENBURPH Jenburkt Pharmaceuticals Limited NSEPHARMA 871.40 11.71 ₹384.57 Cr 2.18% 20.03% 17.63% 7.42% 12.18%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,758.00 34.88 ₹4.22 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,162.00 83.32 ₹2.43 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,615.30 73.73 ₹1.76 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,135.00 25.30 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 634.25 165.17 ₹1.10 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,604.50 52.35 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,002.50 98.99 ₹1.08 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,330.90 31.92 ₹1.08 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026
Revenue 36.89 Cr41.05 Cr35.53 Cr43.02 Cr44.63 Cr
Cost of Revenue 7.19 Cr7.90 Cr6.52 Cr8.79 Cr8.66 Cr
Gross Profit 29.71 Cr33.14 Cr29.01 Cr34.24 Cr35.97 Cr
Operating Expenses 21.66 Cr23.08 Cr20.77 Cr27.64 Cr22.53 Cr
Operating Income 8.04 Cr10.07 Cr8.23 Cr6.60 Cr13.44 Cr
EBITDA 10.40 Cr12.74 Cr11.01 Cr9.24 Cr14.65 Cr
Interest Expense 11.03 L11.13 L10.99 L11.55 L12.92 L
Pretax Income 9.51 Cr11.84 Cr10.18 Cr8.30 Cr13.71 Cr
Tax Provision 3.01 Cr3.30 Cr2.39 Cr2.37 Cr2.86 Cr
Net Income 6.51 Cr8.54 Cr7.79 Cr5.93 Cr10.85 Cr
Diluted EPS -----

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -136.14 Cr141.63 Cr151.69 Cr168.74 Cr
Cost of Revenue -33.81 Cr31.14 Cr29.66 Cr32.33 Cr
Gross Profit -102.33 Cr110.50 Cr122.03 Cr136.41 Cr
Operating Expenses -74.22 Cr79.71 Cr84.37 Cr95.78 Cr
Operating Income -28.11 Cr30.78 Cr37.66 Cr40.63 Cr
EBITDA -35.42 Cr37.75 Cr47.11 Cr50.09 Cr
Interest Expense -29.97 L22.99 L45.28 L46.20 L
Pretax Income -32.86 Cr35.18 Cr43.93 Cr46.52 Cr
Tax Provision -8.26 Cr9.20 Cr11.87 Cr11.78 Cr
Net Income -24.61 Cr25.98 Cr32.06 Cr34.74 Cr
Diluted EPS -53.9058.8672.6578.71

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -141.81 Cr165.10 Cr196.19 Cr226.01 Cr
Current Assets -81.09 Cr109.73 Cr56.53 Cr95.09 Cr
Cash & Equivalents -3.66 Cr4.13 Cr7.36 Cr5.58 Cr
Inventory -8.34 Cr8.56 Cr8.88 Cr13.63 Cr
Receivables -16.96 Cr19.48 Cr20.73 Cr24.36 Cr
Total Liabilities -19.42 Cr20.16 Cr24.41 Cr28.97 Cr
Current Liabilities -15.76 Cr16.38 Cr18.82 Cr23.15 Cr
Long Term Debt -----
Total Debt -2.93 Cr03.89 Cr2.49 Cr
Total Equity -122.39 Cr144.94 Cr171.78 Cr197.04 Cr
Shares Outstanding -45.89 L44.13 L44.13 L44.13 L

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -17.05 Cr8.12 Cr27.91 Cr26.52 Cr
Investing Cash Flow -2.62 Cr-58.04 L-17.04 Cr-19.45 Cr
Financing Cash Flow --21.04 Cr-7.08 Cr-7.62 Cr-8.86 Cr
Capital Expenditure --2.10 Cr-2.55 Cr-19.71 Cr-13.72 Cr
Free Cash Flow -14.95 Cr5.57 Cr8.19 Cr12.80 Cr
Net Change in Cash --1.37 Cr46.55 L3.24 Cr-1.79 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -75.2%78.0%80.4%80.8%
Operating Margin % -20.6%21.7%24.8%24.1%
Net Margin % -18.1%18.3%21.1%20.6%
ROE % -20.1%17.9%18.7%17.6%
ROCE % -22.3%20.7%21.2%20.0%

Shareholding Pattern

Insiders
61.18%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JENBURPH

Google News Wed, 05 Aug 2026

Jenburkt Pharmaceuticals Share Price Rises Over 10% Today - Univest

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxNVmZMV0sxQnlPRFVpbEVLZ2RIcWtxUEJCd3lnUHlFMl8yZzFhQW02SGZMN3dGcGFQbnNrMjNNcTZuODV0dWFTVjNKVGxmYm83N043UHVLVVVxdm1IaWtBQUxNNEdLTjIzRUM2ZmVHTlUwU2taM0RwT3dyRFhYNW5Dc0Y1QlB2ZFpN?oc=5"…

Google News Wed, 07 Oct 2026

Jenburkt Pharmaceuticals Ltd. 52 Week Low Streak: Consecutive Low Analysis - Univest

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOTDRGZ0l0WnlxZG1fUzkxeWpPRlZzQkdqR3JuRGlSZm11bzdzd2JJbE02MUZHQUlveFVDRDVWcXRLSllIdWJpZDBKeUhsSnNOWDFKOHZqTGlLNl9nTEppTEVyVTQ4X3VyRlJXUEZ2M2UxZE42dl9TeGl1X0pkRi1CVlhlcWJkTW1qbkVVc1…

Google News Sat, 27 Jun 2026

AMANTA Stock Price and Chart — NSE:AMANTA - TradingView

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5lV2VCSDJIdzdKNXJXdUN2UXQ3cTNTWHhlNDJ3RTY3S1Noem9KemJfZU54SWU0Z0JCMnhFTS1pM3pfTnVZRldxN0tZQ19zXzNCSFdaS2pkeWR4SEk?oc=5" target="_blank">AMANTA Stock Price and Chart — NSE:AMANTA</a…

Google News Fri, 20 Dec 2024

ANUHPHR Stock Price and Chart — NSE:ANUHPHR - TradingView

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE00OXNmUGRyZnR3ZnBiUTl3M2l5dnJBcjY0M2YzZ3h1QndTY0Y5dHVDaXpPZUZCcTBQMjlCbWlmU3hRX01HeHFwZUFiYzNrcUd3eXZSSFh3X1ZjZU9r?oc=5" target="_blank">ANUHPHR Stock Price and Chart — NSE:ANUHPHR…

Google News ue, 06 Oct 2026

Jenburkt Pharmaceuticals Share Price: Price, Valuation View - Univest

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOeUJfVFBSYzNlbTFJeWdOSU9jS2dZU1FGU29Id282WGxxb3owYzBWY3FaYnk4ZkdMY2dwempnRERzTEFNY2lnYXEyYmNIcV9WeXI0WWNhUDRPU003b0VSd3FfOHMzYm4yd0dMODRxMVF0U0ZOWF8xeTFBcnRrSnp1bXkybHRwTTV3ZEZJOT…

Google News Wed, 28 May 2025

VALIANTLAB Stock Price and Chart — NSE:VALIANTLAB - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1WaVRBTVJrR3p2dGtDVHMxbllHd3V5MXlsVmVLZW1wQ2R4cXQwZHZOcU03eUR4Ul9VSWVOYnpZLXFCLUVFM1dhMExOME9hczNqNFJTUHc0NUR6SXJ2aHQ4eg?oc=5" target="_blank">VALIANTLAB Stock Price and Chart — NS…

JENBURPH — Frequently Asked Questions

What is the current share price of Jenburkt Pharmaceuticals Limited (JENBURPH)?

As of 2026-10-24 04:55 IST, Jenburkt Pharmaceuticals Limited (JENBURPH) trades at ₹871.40 on NSE. Its 52-week range is ₹871.40 to ₹1,051.20.

What is the market capitalisation of JENBURPH?

Jenburkt Pharmaceuticals Limited (JENBURPH) has a market capitalisation of ₹384.57 Cr on NSE.

What is the P/E ratio of JENBURPH?

JENBURPH trades at a trailing price-to-earnings (P/E) ratio of 11.71. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 2.12.

Does JENBURPH pay a dividend?

Jenburkt Pharmaceuticals Limited (JENBURPH) currently offers a dividend yield of 2.18%.

What is the return on equity (ROE) of JENBURPH?

JENBURPH has a return on equity (ROE) of 17.63%. Its return on capital employed (ROCE) is 20.03%.

Is JENBURPH a good stock to buy?

This page provides a data-driven analysis of Jenburkt Pharmaceuticals Limited (JENBURPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space